NEW YORK — ZPredicta said on Thursday that it has partnered with Laboratory Corporation of America to develop and commercialize tumor-specific preclinical models based on its 3D cell culture platform.
ZPredicta's platform integrates organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing. The San Jose, California-based company said that the alliance with LabCorp will help expand the platform's use for preclinical testing and research studies.
Specific terms of the deal were not disclosed.
"LabCorp is one of the world’s leading life science companies and its drug development business, Covance, is one of the leading end-to-end development partners for the biopharmaceutical industry," ZPredicta Founder and CEO Julia Kirshner said in a statement. "With this strategic relationship, we are well positioned to offer our cell culture technology to a much larger customer base and also to expand the number of cell culture models that we offer."